Literature DB >> 20876240

Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.

A Gallini1, E Degris, M Desplas, R Bourrel, M Archambaud, J-L Montastruc, M Lapeyre-Mestre, A Sommet.   

Abstract

BACKGROUND: The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital.
OBJECTIVE: To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital.
METHODS: An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year.
RESULTS: Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability.
CONCLUSIONS: This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876240     DOI: 10.1093/jac/dkq351

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Regional variations in quinolone use in France and associated factors.

Authors:  A Gallini; F Taboulet; R Bourrel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-29       Impact factor: 3.267

2.  Influence of primary care antibiotic prescribing on incidence rates of multidrug-resistant Gram-negative bacteria in hospitalised patients.

Authors:  Munther S Alnajjar; Mamoon A Aldeyab; Michael G Scott; Mary P Kearney; Glenda Fleming; Fiona Glimore; David Farren; James C McElnay
Journal:  Infection       Date:  2019-05-07       Impact factor: 3.553

Review 3.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

4.  Long-term outcomes of an antimicrobial stewardship program implemented in a hospital with low baseline antibiotic use.

Authors:  Timothy C Jenkins; Bryan C Knepper; Katherine Shihadeh; Michelle K Haas; Allison L Sabel; Andrew W Steele; Michael L Wilson; Connie S Price; William J Burman; Philip S Mehler
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03-05       Impact factor: 3.254

5.  Addressing the Unknowns of Antimicrobial Resistance: Quantifying and Mapping the Drivers of Burden.

Authors:  Gwenan M Knight; Ceire Costelloe; Kris A Murray; Julie V Robotham; Rifat Atun; Alison H Holmes
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

6.  Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?

Authors:  O Grignon; E Montassier; S Corvec; D Lepelletier; J-B Hardouin; J Caillon; E Batard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-23       Impact factor: 3.267

7.  The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

8.  Preferential Use of Nitrofurantoin Over Fluoroquinolones for Acute Uncomplicated Cystitis and Outpatient Escherichia coli Resistance in an Integrated Healthcare System.

Authors:  Rebecca L Pedela; Katherine C Shihadeh; Bryan C Knepper; Michelle K Haas; William J Burman; Timothy C Jenkins
Journal:  Infect Control Hosp Epidemiol       Date:  2017-01-05       Impact factor: 3.254

9.  Effects of clinical pathways for common outpatient infections on antibiotic prescribing.

Authors:  Timothy C Jenkins; Amy Irwin; Letoynia Coombs; Lauren Dealleaume; Stephen E Ross; Jeanne Rozwadowski; Brian Webster; L Miriam Dickinson; Allison L Sabel; Thomas D Mackenzie; David R West; Connie S Price
Journal:  Am J Med       Date:  2013-04       Impact factor: 4.965

10.  Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012.

Authors:  Larissa May; Eili Y Klein; Richard E Rothman; Ramanan Laxminarayan
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.